tbuckley/cabot-search huggingface dataset:
NSAIDs in axial spondyloarthritis: to be continued…?
Authors: G Varkas, F Van den Bosch
Journal: Annals of the Rheumatic Diseases (2016)

Phenylbutazone was discovered in 1946 and promptly exhibited efficacy in various rheumatic diseases in the early 1950s. Its efficacy on pain and general well-being was especially present in ankylosing spondylitis (AS), which was then known as ‘rheumatoid spondylitis’.1 ,2 However, even in the early days, non-steroidal anti-inflammatory drugs (NSAIDs) were not considered harmless drugs, as the toxic properties on bone marrow or the gastrointestinal tract, and the appearance of oedema or skin rash, although commonly reversible, were already apparent from the start. Up until now, a various range of NSAIDs have taken centre stage and have been the cornerstone of treatment of patients with spondyloarthritis (SpA).3 ,4 Despite the common use of these drugs for almost seven decades, there are still a number of unanswered questions, such as which type of NSAIDs we should preferentially use in axial SpA (AxSpA) and whether these agents should be given continuously or on demand.

All NSAIDs are effective anti-inflammatory drugs because of their ability to inhibit the biosynthesis of prostaglandins at the level of the cyclo-oxygenase (COX) enzyme; however, this mode of action also explains a number of side effects. While selective COX-2 inhibitors have claimed to induce fewer side effects through the omission of COX-1 inhibition, large meta-analyses have failed to demonstrate this superiority of COX selectivity in vascular and complicated gastrointestinal outcomes compared with conventional NSAIDs.5 ,6 Furthermore, head-to-head comparisons of efficacy in AxSpA regarding the available NSAIDs are scarce. In AS, the treatment effect of piroxicam 20 mg, meloxicam 15 mg and meloxicam 22.5 mg did not differ significantly after 1 year of treatment regarding the patient’s overall assessment,7 and Sieper et al 8 reported that the efficacy of diclofenac compared with celecoxib was non-inferior regarding symptom relief. In contrast, other studies have demonstrated superior efficacy of …
Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy
Authors: Jeffrey A. Moscow, Hui Huang, Charles Carter, Kenneth Hines, JoAnne Zujewski, Georgie Cusack, Cathy Chow, David Venzon, Brian Sorrentino, Yawen Chiang, Barry Goldspiel, Susan Leitman, Elizabeth J. Read, Andrea Abati, Michael M. Gottesman, Ira Pastan, Stephanie Sellers, Cynthia Dunbar, Kenneth H. Cowan
Journal: Blood (1999)
Filaggrin Associated Risk for Atopic Dermatitis Is Offset By Protective Missense Variants in Rptn and LCE1B Genes in the Epidermal Differentiation Complex
Authors: Rasika A. Mathias, Meher Boorgula, Sameer Chavan, Kruthika R. Iyer, Nicholas M. Rafaels, Joseph Potee, Jon M. Hanifin, Amy S. Paller, Lynda C. Schneider, Richard L. Gallo, Emma Guttman-Yassky, Peck Y. Ong, Ingo Ruczinski, Terri H. Beaty, Li Gao, Lisa A. Beck, Donald Y.M. Leung, Kathleen C. Barnes
Journal: Journal of Allergy and Clinical Immunology (2016)
Effect of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in a patient with spinal cord injury.
Authors: Shinjiro Muneta, Takeru Iwata, Kunio Hiwada, Eiki Murakami, Yuzuru Sato, Yoichi Imamura
Journal: Circulation (1992)

A 72-year-old female who underwent the extirpation of metastatic intraspinal tumor showed an extremely wide variation of blood pressure with recurrent episodes of syncope due to paroxysmal hypotension. Treatment of the patient with salt supplement and L-threo-3, 4-dihydroxyphenylserine, an exogenous precursor of norepinephrine, markedly improved the syncopal attack as well as the daily activity.
P63 * LIGAND-ACTIVATED TRANSCRIPTION FACTORS PPAR AND PPAR EXPRESSION IN HUMAN GLIOMA
Authors: H. R. Haynes, M. Ginty, K. Kemp, H. Williams, S. M. Pollard, P. White, N. Scolding, A. Wilkins, K. M. Kurian
Journal: Neuro-Oncology (2014)

INTRODUCTION: Agonists of the ligand-activated transcription factors PPARγ and PPARα are in routine clinical use for Type 2 diabetes and lipid control. In vitro studies suggest that PPARγ and PPARα exert antiproliferative and anti-invasive effects on gliomas. PPAR may therefore have a role as a diagnostic and prognostic biomarker or drug target in human gliomas. METHOD: 52 brain tumour samples diagnosed 2011-2013 (34 WHO Grade IV, 14 WHO Grade III, 4 WHO Grade II gliomas), banked at the Brain Tumour Bank Southwest UK were analysed for PPARγ and PPARα expression using dot and western blot techniques. mRNA expression was quantified using rt-PCR. The expression of PPARγ and PPARα was compared with survival data and stratified by WHO tumour grade. RESULTS: In our study PPARγ and PPARα protein expression differs with WHO glioma grade. WHO grade III gliomas show a higher expression of both PPARγ and PPARα when compared with WHO grade IV gliomas. CONCLUSION:Our results show for the first time that both PPARγ and PPARα protein expression is significantly increased in WHO grade III gliomas compared to WHO grade IV gliomas. PPARγ and PPARα agonists are in current clinical use and future trials stratified by PPARγ and PPARα expression may reveal a patient cohort with optimum clinical response to these agents.
Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis
Authors: Valerie Hox, Michael P. O'Connell, Jonathan J. Lyons, Paul Sackstein, Thomas Dimaggio, Nina Jones, Celeste Nelson, Manfred Boehm, Steven M. Holland, Alexandra F. Freeman, David J. Tweardy, Ana Olivera, Dean D. Metcalfe, Joshua D. Milner
Journal: Journal of Allergy and Clinical Immunology (2016)
Concurrent Neoadjuvant Chemoradiotherapy for Siewert Ii and III Adenocarcinoma of the Gastroesophageal Junction: Short Term Efficacy
Authors: Q. Zhao, Y. Li, J. Wang, J. Zhang, X. Qiao, Y. Tian, P. Yang, B. Tan, L. Fan, G. Shi, Q. Xu, R. Li, Y. Liu, Z. Jiao, X. Zhao, D. Wang, Z. Zhang, Y. Liu
Journal: Annals of Oncology (2014)
Suppression of Lipid Mediators By the Humanized Anti-IgE Antibody Omalizumab in Aspirin-Exacerbated Respiratory Disease
Authors: Hiroaki Hayashi, Chihiro Mitsui, Yuma Fukutomi, Keiichi Kajiwara, Kentaro Watai, Arisa Kinoshita, Yosuke Kamide, Kiyoshi Sekiya, Takahiro Tsuburai, Akio Mori, Kazuo Akiyama, Yoshinori Hasegawa, Masami Taniguchi
Journal: Journal of Allergy and Clinical Immunology (2016)
Abstract 17545: Ex vivo Evaluation of Coronary Yellow Plaque on Coronary Angioscopy: A Histopathological Validation Study
Authors: Masahiko Shibuya, Hiroyuki Hao, Fujii Kenichi, Fukunaga Masashi, Miki Kojiro, Imanaka Takahiro, Kawasaki Daizo, Masutani Motomaru, Ohyanagi mitsumasa, Masuyama Tohru
Journal: Circulation (2012)

Background: Yellow color intensity of coronary plaque evaluated by coronary angioscopy (CAS) might be associated with plaque vulnerability. However, the histopathological comparison data is limited...
Ghrelin, adiponectin and leptin in cancer cachexia
Authors: I. Wolf, S. Sadetzki, H. Kanety, Y. Kundel, C. Pariente, B. Oberman, R. Catane, B. Kaufman, I. Shimon
Journal: Journal of Clinical Oncology (2005)

8113 Background: The hormone ghrelin and the adipocytokines leptin and adiponectin participate in body weight regulation. In response to severe weight loss, ghrelin and adiponectin levels increase and leptin decreases. Here we studied the association between plasma levels of these mediators and cancer cachexia. Methods: Study population included breast (n=14) and colon (n=26) cancer patients. The mean age was 65±14. Fasting plasma ghrelin, adiponectin and leptin levels, as well as weight loss, were determined prior to administration of cancer therapy. Patients who had other acute or chronic cachectic states were excluded. Results: Patients were classified as either cachectics (defined as ≥5% loss of body mass index, n=18) or non-cachectics (n=22). Similar distribution of age, gender and diagnosis was observed in both study groups, but the cachectic patients had higher rates of metastatic disease and lower albumin levels (p<0.02 for both variables). Mean plasma ghrelin levels (pg/ml) were higher among cachectic compared to non-cachectic patients, for all categories examined (table). Yet, statistical significance was not reached for the differences between cachectic and non-cachectic men and colon cancer patients (table). Notably, the association between ghrelin levels and weight loss was only modest (r=-0.49) and in a third of the cachectic patients, ghrelin levels were equal or lower than the mean levels of the non-cachectic group. Mean plasma adiponectin levels were higher among cachectic patients compared to the control (12.3±5.2 ng/ml vs. 9.6±3.6 ng/ml respectively, p=0.06). Mean leptin levels were similar in both study groups. No correlation was found between ghrelin, adiponectin and leptin levels. Conclusions: Baseline plasma ghrelin and adiponectin levels are high among cancer cachexia patients. Yet, these expected physiologic responses are absent in a significant proportion of these patients and seem be gender and tumor type dependent. No significant financial relationships to disclose.
Virus Studies With Germfree Mice. I. Preparation of Serologic Diagnostic Reagents and Survey of Germfree and Monocontaminated Mice for Indigenous Murine Viruses&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: John C. Parker, Raymond W. Tennant, Thomas G. Ward, Wallace P. Rowe
Journal: JNCI Journal of the National Cancer Institute (1965)

Sera of germfree mice of two different strains were examined for evidence of immunological contact with reovirus 3, pneumonia virus of mice, polyoma, K, Theiler's mouse encephalomyelitis, Sendai, mouse adenovirus, and mouse hepatitis viruses. All tests were negative, which is in contrast to the status of conventional mice similarly examined. In addition, no evidence was obtained for the presence in these germfree mice of lymphocytic choriomeningitis virus or the plasma lactic dehydrogenase-stimulating agent. No evidence for inapparent or subclinical infection with certain of these viruses was obtained with the mouse antibody production test. The germfree barrier appears to offer effective protection against several viruses commonly in conventional mouse populations.
Technical Guidance on HIV Counseling
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer
Authors: Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, Steven J. Cohen
Journal: Journal of the National Comprehensive Cancer Network (2014)

Appendiceal malignancies are rare and represent 1% of intestinal tumors in the United States. The role and efficacy of modern systemic therapy in advanced appendiceal adenocarcinoma has not been established. This study analyzed patients with recurrent or metastatic appendiceal adenocarcinoma in the database for Colorectal Cancer (CRC; 2005-2012). This database tracks longitudinal care for patients treated at 8 specialty centers across the Unites States. Study objectives were to describe and evaluate the efficacy of systemic therapy and investigate relationships with clinicopathologic features. Cox regression analysis was performed to identify predictors of progression-free survival (PFS) and overall survival (OS). Of 248 patients with advanced appendiceal carcinoma, 112 (45%) received systemic therapy for measurable disease and are the focus of this report. The most common chemotherapy regimens included FOLFOX with or without bevacizumab (n=39 and n=37, respectively), FOLFIRI (n=15), and single-agent fluoro-pyrimidine (n=10). Among 99 patients evaluable for best response, 39 experienced a response (response rate [RR], 39%) and 36 (36%) had stable disease. The median PFS was 1.2 years (95% CI, 1.0-1.8) and median OS was 2.1 years (95% CI, 1.6-2.3). Patients with non-mucinous histology or high-grade tumors and those who underwent nondebulking surgery had worse PFS and OS. Treatment of advanced appendiceal adenocarcinoma at NCCN Member Institutions commonly incorporates agents used for CRC. RR, PFS, and OS are comparable to those achieved in the treatment of metastatic CRC. Poor prognostic factors include nonmucinous histology or high-grade tumors and history of nondebulking surgery.
Application of a robust and novel ex vivo platform mimicking patient heterogenous tumor microenvironment for personalized cancer treatment.
Authors: Kanaka Govind Babu, Biswanath Majumder, Saravanan Thiyagarajan, Baraneedharan Ulaganathan, Rajagopal Surindran, Ashok Shenoy, Moni A. Kuriakose, Massimo Loda, Rameen Beroukhim, Peleg Horowitz, Shivani Agarwal, Padhma Radhakrishnan, Mallik Sundaram, Shiladitya Sengupta, Pradip K. Majumder
Journal: Journal of Clinical Oncology (2015)

6029 Background: Predicting clinical response to anticancer drugs remains a major challenge in the management of cancer. Recent advances show that Tumor Micro Environment (TME) and heterogeneity impact therapy outcomes; indicating the limitations of biomarker-guided strategies for personalizing therapy. There is a need for platforms that can predict treatment outcome with high fidelity by contextually integrating tumor heterogeneity and phenocopying the TME. Methods: Tumor and grade-matched matrix support along with autologous sera from individual patients were used to engineer personalized Tumor Ecosystems (TE) in head and neck, breast and colorectal cancers. We evaluated functional outcomes as a measure of response to a panel of anticancer drugs in this platform. In the training data set obtained from a cohort of 109 patients, TE read-outs were integrated with their corresponding clinical outcomes for generation of a machine learning (M-score) algorithm to predict clinical response to these drugs. This algorithm was further validated in a test group of 55 new patients. Results: Histopathological and molecular characterization of the tumor slices cultured in TEs revealed a close approximation to the parental tumor at baseline as confirmed by Ki-67 index, critical phosphoproteomic status, global transcriptomic profiles and balance in active components of tumor and stromal phenotypes. The M-score algorithm when applied to the test cohort of more than 100 patient tumors assessed in the functional TE achieved 100% sensitivity while keeping specificity in a desired high range for predicting short term clinical outcome. Conclusions: The high specificity and sensitivity observed in predicting clinical outcomes using the TE supports the use of this novel platform for personalized cancer treatment. (Part of the data is accepted in Nature Communication).
Suramin: is adaptive control necessary?
Authors: K Kobayashi, E E Vokes, K Stefansson, L Janisch, N J Vogelzang, F Berezin, M J Ratain
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.12.1984 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1453214 Suramin: is adaptive control necessary? K KobayashixK KobayashiSearch for articles by this author , E E VokesxE E VokesSearch for articles by this author , K StefanssonxK StefanssonSearch for articles by this author , L JanischxL JanischSearch for articles by this author , N J VogelzangxN J VogelzangSearch for articles by this author , F BerezinxF BerezinSearch for articles by this author , M J RatainxM J RatainSearch for articles by this author Show More https://doi.org/10.1200/JCO.1992.10.12.1984 PDF "Suramin: is adaptive control necessary?." Journal of Clinical Oncology, 10(12), pp. 1984–1985© 1992 by American Society of Clinical Oncology
Murine Oncornavirus Activation in the Pancreas During Infection With Venezuelan Equine Encephalitis Virus
Authors: Alyne K. Harrison, Frederick A. Murphy
Journal: JNCI Journal of the National Cancer Institute (1975)

Electron microscopic studies of the pancreases of 3-week-old ICR Swiss mice infected with Venezuelan equine encephalitis virus and killed 6 days post inoculation (at which time they were moribund) indicated significantly more type-C particles than were found in uninfected controls. This phenomenon was apparently possible because of the microanatomy of the pancreas, in which interstital spaces allowed accumulation of virus particles.
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia
Authors: C M Lucas, M Milani, M Butterworth, N Carmell, L J Scott, R E Clark, G M Cohen, S Varadarajan
Journal: Leukemia (2016)

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies, including imatinib-treated chronic myeloid leukemia (CML). Although high CIP2A levels correlate with disease progression in CML, the underlying molecular mechanisms remain elusive. In a screen of diagnostic chronic phase samples from patients with high and low CIP2A protein levels, high CIP2A levels correlate with an antiapoptotic phenotype, characterized by downregulation of proapoptotic BCL-2 family members, including BIM, PUMA and HRK, and upregulation of the antiapoptotic protein BCL-XL. These results suggest that the poor prognosis of patients with high CIP2A levels is due to an antiapoptotic phenotype. Disrupting this antiapoptotic phenotype by inhibition of BCL-XL via RNA interference or A-1331852, a novel, potent and BCL-XL-selective inhibitor, resulted in extensive apoptosis either alone or in combination with imatinib, dasatinib or nilotinib, both in cell lines and in primary CD34+ cells from patients with high levels of CIP2A. These results demonstrate that BCL-XL is the major antiapoptotic survival protein and may be a novel therapeutic target in CML.
Enterobacter sakazakii
Journal: JAMA (2002)

Describes the results of research dynamics of bacteria E. sakazakii in milk with different fat in it and with different
low-temperature storage conditions. It was found that with the same initial quantity of bacteria E. sakazakii in simulated
milk samples, increesed with highest temperature storage. Thus, low temperature storage of milk samples (4 °C),
the largest number of bacteria E. sakazakii was from 9 000 KUO/cm³ to 10 000 KUO/cm³, and a temperature of 10 °C –
10 000 KUO/cm³ to 17 000 KUO/cm³. Also, it was found that the dynamics of bacteria E. sakazakii effectively decreases when storing milk at a temperature of 4°C and content of fat is 4.5% and 4%.
Long-term outcome of hepatitis C infection after bone marrow transplantation
Authors: Régis Peffault de Latour, Vincent Lévy, Tarik Asselah, Patrick Marcellin, Catherine Scieux, Lionel Adès, Richard Traineau, Agnès Devergie, Patricia Ribaud, Hélène Espérou, Eliane Gluckman, Dominique Valla, Gérard Socié
Journal: Blood (2003)
The Child or Adolescent with Elevated Blood Pressure
Authors: Stephen Sammut, Nevianna Tomson, Pippa Corrie
Journal: New England Journal of Medicine (2014)

ic effects associated with vemurafenib are also responsible for the development of pyogenic granulomas.If this is the case, treatment with dual BRAF and MEK inhibition might prevent eruption of these lesions, in keeping with trial data showing that combined inhibition results in a significantly lower incidence of dermatologic events. 5
HLA-A,B,C and DR Alloantigen Expression on Forty-Six Cultured Human Tumor Cell Lines2
Authors: Marilyn S. Pollack, Socorro D. Heagney, Philip O. Livingston, Jørgen Fogh
Journal: JNCI Journal of the National Cancer Institute (1981)

Journal Article HLA-A,B,C and DR Alloantigen Expression on Forty-Six Cultured Human Tumor Cell Lines Get access Marilyn S. Pollack, Marilyn S. Pollack Search for other works by this author on: Oxford Academic PubMed Google Scholar Socorro D. Heagney, Socorro D. Heagney Search for other works by this author on: Oxford Academic PubMed Google Scholar Philip O. Livingston, Philip O. Livingston Search for other works by this author on: Oxford Academic PubMed Google Scholar Jørgen Fogh Jørgen Fogh Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 66, Issue 6, June 1981, Pages 1003–1012, https://doi.org/10.1093/jnci/66.6.1003 Published: 01 June 1981 Article history Received: 24 March 1980 Accepted: 25 November 1980 Published: 01 June 1981
&lt;italic&gt;Brief Communication:&lt;/italic&gt; Desmosterol in Rat Central and Peripheral Nervous Systems During Normal and Neoplastic Growth&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: J F Weiss, H Cravioto, J Ransohoff
Journal: JNCI Journal of the National Cancer Institute (1975)

Desmosterol (5, 24-cholestadien-3beta-ol; delta 24-cholesterol; 24-dehydrocholesterol), an immediate precursor of brain cholesterol, increased in malignant intracranial tumors induced in rats by nitrosourea derivatives. The average increase in desmosterol was higher in intracerebral gliomas than in neurinomas of the trigeminal nerve. Similarly, desmosterol increased only slightly in developing normal trigeminal nerve compared to the high levels observed in developing cerebrum. The differences may have been partly related to the predominantly growing cell type, i.e., glial (central nervous system) or Schwann (peripheral nervous system) cells seen at the time of study.
Methylation of Liver and Kidney Ribonucleic Acids in Newborn Rats Treated With &lt;italic&gt;H&lt;/italic&gt;&lt;sup&gt;3&lt;/sup&gt;-Dimethylnitrosamine&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: K Y LEE, K SPENCER
Journal: JNCI Journal of the National Cancer Institute (1964)

Journal Article Methylation of Liver and Kidney Ribonucleic Acids in Newborn Rats Treated With H3-Dimethylnitrosamine Get access K. Y. Lee, K. Y. Lee Division of Oncology, Institute for Medical Research, The Chicago Medical School, Chicago, Illinois Search for other works by this author on: Oxford Academic PubMed Google Scholar K. Spencer K. Spencer Division of Oncology, Institute for Medical Research, The Chicago Medical School, Chicago, Illinois Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 33, Issue 6, December 1964, Pages 957–961, https://doi.org/10.1093/jnci/33.6.957 Published: 01 December 1964 Article history Received: 11 May 1964 Published: 01 December 1964